Safety and Efficacy of WIN-901X in Asthma

Double Blinded, Randomized, Placebo Controlled, Multi-center, Phase 2 : Exploratory Clinical Study to Evaluate the Efficacy, Dose-response and Safety of WIN-901X in Asthma Patients

This clinical trial is designed to evaluate the efficacy, dose-response and safety of WIN-901X in Asthma patients.

Double blinded, Randomized, Placebo Controlled, Multi-center, Phase 2 : Exploratory Clinical Study to Evaluate the Efficacy, Dose-response and Safety of WIN-901X in Asthma Patients

Inclusion Criteria:

• Greater than or equal to 20 and less than 80 years of age
• Have physician diagnosed asthma with irreversible airway obstruction at least 6 months prior to the screening
• FEV1 between 60% and 85% before inhaling fast-acting bronchodilator at screening
• No history of smoking at least one year prior to the screening
• Having voluntarily signed an informed consent

Exclusion Criteria:

• Have visited emergency room due to the worsening asthma symptoms, within 4 weeks before the screening
• Have been hospitalized due to an acute worsening of asthma within 3 months before the screening
• Have a history of laryngitis, pyrexia, sinusitis, otitis media, respiratory tract infection, and infectious rhinitis within 4 weeks prior to the screening
• Have malignant tumor